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Abstract
The spatial heterogeneity in magnetic resonance (MR) metabolic and diffusion parameters and their relationship
were studied for patients with treatment-naive grade 3 gliomas. MR data were evaluated from 51 patients with
newly diagnosed grade 3 gliomas. Anatomic, diffusion, and metabolic imaging data were considered. Variations
in metabolite levels, apparent diffusion coefficient (ADC), and fractional anisotropy (FA) were evaluated in regions
of gadolinium enhancement and T2 hyperintensity as well as regions with abnormal metabolic signatures. Contrast
enhancement was present in only 21 of the 51 patients. When present, the enhancing component of the lesion
had higher choline-to–N -acetylaspartate index (CNI), higher choline, lower N -acetylaspartate, similar creatine,
similar ADC and FA, and higher lactate/lipid than the nonenhancing lesion. Regions with CNI ≥ 4 had higher cho-
line, lower N -acetylaspartate, higher lactate/lipid, higher ADC, and lower FA than normal-appearing white matter
and regions with intermediate CNI values. For lesions that exhibited gadolinium enhancement, the metabolite lev-
els and diffusion parameters in the region of enhancement were consistent with it corresponding to the most
abnormal portion of the tumor. For nonenhancing lesions, areas with CNI ≥ 4 were the most abnormal in meta-
bolic and diffusion parameters. This suggests that the region with the highest CNI might provide a good target
for biopsies for nonenhancing lesions to obtain a representative histologic diagnosis of its degree of malignancy.
Metabolic and diffusion parameter levels may be of interest not only for directing tissue sampling but also for
defining the targets for focal therapy and assessing response to therapy.
Translational Oncology (2012) 5, 10–18
Introduction
The incidence rate of brain tumors is increasing, with an estimated
22,020 new cases of primary brain tumors being detected each year
in the United States [1]. For adults older than 45 years, 90% of such
tumors are diagnosed as gliomas. These lesions are infiltrative in na-
ture, which makes it difficult to define tumor margins and to specify
which regions should be targeted for focal therapy. Grade 2 gliomas
have the best prognosis with a median survival of 7.9 years [2], grade 3
gliomas have intermediate survival with a median of 33.5 months [3],
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and grade 4 gliomas are the most malignant with a median survival
of 40.9 weeks [4]. Whereas the initial therapeutic strategy is maximal
safe resection for all types of glioma, next-line therapies differ for pa-
tients with grade 2 versus grade 3 or 4 lesions, with radiation and, in
some cases, chemotherapy being delayed until the time of recurrence.
Making an accurate histologic diagnosis is especially critical for grade 3
lesions, which often look relatively uniform on T2-weighted mag-
netic resonance (MR) images and have little or no enhancement on
post-gadolinium T1-weighted images. In practice, the underlying
biological properties of different regions of the tumor may be quite var-
iable, and there may be regions with characteristics of grade 2 and grade
3 histologic diagnosis within the same tumor. The development of non-
invasive imaging methods that define tumor heterogeneity and can
be used to direct tissue sampling to the most malignant region of the
tumor is a priority for optimizing patient care.
One of the methods proposed for characterizing the heterogeneity
of both enhancing and nonenhancing regions of glioma is metabolic
imaging using MR spectroscopic imaging (MRSI). When used in
combination with standard MR imaging (MRI), this has been has
been shown to contribute to brain tumor diagnosis and localization
[5–11], staging [12–15], assessment of progression [14,16–18],
treatment planning [19–23], and response to therapy [24–29]. Long
echo time MRSI, which is the most commonly applied method, pro-
vides arrays of spectra that are characterized by three major metabo-
lite peaks in healthy brain tissue: choline (Cho), total creatine (Cr),
and N -acetylaspartate (NAA). An increase in Cho provides a marker
for increased proliferation or membrane turnover. The Cr peak reflects
bioenergetic processes, and NAA is an indicator of neuronal viability
that is observed to be significantly lower in tumors than regions of
normal brain. Singlet lipid and doublet lactate peaks occur at similar
spectral frequencies and may also be observed in the disease state.
Lactate is a byproduct of anaerobic glycolysis and is present in regions
of tumor as a result of poor oxygenation. Lipid is present in the bilayer
of the cell membrane, and its presence indicates membrane breakdown
and a more aggressive tumor phenotype.
Diffusion tensor imaging (DTI) is another MR technique that has
been proposed as adding information on heterogeneity in the structural
properties of different types of tissue. DTI acquires images with diffu-
sion gradients applied in multiple directions, and uses these images to
generate pixel by pixel estimates of the coefficients of the corresponding
tensor matrix. The eigenvalues and eigenvectors derived from the ten-
sor are used for computing maps of the apparent diffusion coefficient
(ADC) and fractional anisotropy (FA). ADC values have been shown to
increase in regions of infiltrative tumor and surrounding edema [30–
34]. The values of FA provide an assessment of the directionality of
water diffusion and have been shown to decrease in brain tumors
due to disruptions in tissue architecture [30,31,34–36].
The current study evaluates data acquired from patients with
treatment-naive grade 3 gliomas with respect to regional differences
in MRSI and DTI parameters in enhancing and nonenhancing le-
sions. Of particular interest was to determine which MR parameters
highlighted regions of the tumor that were likely to be malignant and
might therefore be considered as targets for obtaining tissue during
surgical resection to make an accurate histologic diagnosis.
Materials and Methods
MRI data of 51 patients with newly diagnosed supratentorial grade 3
glioma according to WHO stage II classification and who had been
scanned 1 day before surgery were selected for this study (25 men and
26 women; median age = 40 years [range = 21-78 years]; 31 anaplastic
astrocytomas [AAs], 7 anaplastic oligodendrogliomas [OD3s], 13 ana-
plastic oligoastrocytomas [OA3s]). The patients were scanned on a
1.5-T GE Signa Echospeed scanner (GE Medical Systems, Milwaukee,
WI). All patients provided informed consent for participating in the
study, based on a protocol approved by the Committee on Human Re-
search at our institution. A biopsy was performed during the surgery. The
biopsy specimens were taken from the contrast-enhanced portion of the
contrast-enhancing lesions. For nonenhancing lesions, multiple speci-
mens were taken from different areas within the T2 hyperintense area.
The clinical diagnosis was made by a neuropathologist, and the diagnosis
was independently approved by a second neuropathologist.
The MRI protocol included an axial T2-weighted fast spin echo
(FSE) sequence (repetition time [TR] = 3000 milliseconds, echo time
[TE] = 105 milliseconds, matrix size = 192 × 256 × 120, field of view =
195 × 260 × 180 mm, slice thickness = 1.5 mm), and post-Gd-
diethylenetriaminepentacetate (DTPA) T1-weighted spoiled gradient
recalled (SPGR) sequence (TR = 34 milliseconds, TE = 3 milliseconds,
flip angle = 35 degrees, matrix size = 192 × 256 × 124, field of view =
195 × 260 × 186 mm, slice thickness = 1.5 mm).
MRSI data were referenced to the SPGR images and were acquired
using three-dimensional point-resolved spectroscopic (PRESS) [37] for
volume localization with spectral spatial pulses [38] and very selective
suppression [39] outer volume suppression bands (TR = 1000 milli-
seconds, TE = 144 milliseconds, matrix size = 12 × 12 × 8, field of
view = 120 × 120 × 80 mm, 1-ml nominal spatial resolution). Spectral
data from 30 patients were acquired with J-difference lactate editing
that allowed separation of lactate and lipid resonance [40].
MRSI data were quantified offline to estimate the levels of Cho,
Cr, NAA, combined lactate and lipid (LL) for regular spectra, and
separate lactate (Lac) and lipid levels for lactate-edited spectra using
in-house software described in detail in a previous report [41]. Spec-
tral values were normalized relative to the noise levels of the right
hand end of the spectra. The Cho-to-NAA index (CNI) [42], which
defines the distance between the Cho and NAA values for a given
voxel and a regression line that was fit to the normal voxels in a given
subject, was also computed. CNI values are expected to increase in
the tumor because of the reduction in NAA and increase in Cho.
DTI sequences with six gradient directions were acquired in the axial
planes with a b value of 1000 sec/mm2 (TR = 5000 milliseconds, TE =
105 milliseconds, matrix size = 256 × 256 × 40, field of view = 440 ×
440 × 84 mm, slice thickness = 2.1 mm). DTI images were quantified
to calculate the ADC and FA maps using the standard formulas [43].
Diffusion maps were resampled to the resolution of spectral data and
normalized relative to the mean of the voxels in normal-appearing white
matter (NAWM) to form maps of nADC and nFA.
Regions of contrast enhancement (the CE lesion) and T2 hyper-
intensity were defined manually by tracing the abnormality borders
on the SPGR and FSE slices using interactive in-house software by
experienced research assistants and were verified by an experienced
radiation oncologist. The NE lesion was defined as the regions of T2
hyperintensity that excluded the CE lesion. Metabolically abnormal re-
gions were defined as voxels with CNI values of 2 or greater based on
previous results [11]. CNI maps were then used to automatically gen-
erate three regions with distinct levels of metabolic abnormality, 2 ≤
CNI < 3 (CNI2-3), 3 ≤ CNI < 4 (CNI3-4), and CNI ≥ 4 (CNI >
4). Figure 1 shows an example of the regions analyzed for this study.
A total of 11,861 voxels of data were considered from the PRESS-
localized volumes, including 2286 from the NE lesion, 778 from the
Translational Oncology Vol. 5, No. 1, 2012 Spatial Characterization of Grade 3 Gliomas Ozturk-Isik et al. 11
CNI2-3 region, 432 from the CNI3-4 region, 687 from the CNI >
4 region, and 68 from the CE lesion. A single median value was cal-
culated for each spectral or diffusion parameter within a given region
of interest. A Wilcoxon signed rank test was applied to detect paired
significant differences of medians for spectral or diffusion values be-
tween the tumor regions and NAWM for all the patients. For compari-
son of values between patients, the metabolite levels were normalized to
the levels in NAWM and Spearman rank correlation coefficients were
calculated to detect correlations of diffusion and spectral parameters
within the regions of interest. The Holm test was used for multiple
comparisons correction. A sequentially increasing P value was used for
pairwise region comparisons for each parameter, and a Pj value of less
than .05 / (k − j + 1) was considered significant where j = 1,…, k and
k was the total number of comparisons.
Results
Tumor Spatial Extent and Coverage
All the grade 3 patients included in this study exhibited a region of
T2 hyperintensity. The median percentage of the NE lesion within
the PRESS box was 54.2% (min = 27.9%, max = 83.3%). Of
51 patients, 21 exhibited CE on the SPGR images after the injection
of Gd-DTPA. Five of these patients showed minimal CE, and in
one patient, the PRESS-selected volume did not fully cover the
CE lesion. This left 16 of 51 patients with CE lesions that could
be evaluated. All of the patients had CNI2-3 regions, 48 patients
had CNI3-4 regions, and 44 patients had regions with CNI > 4.
Overlap of Anatomic Tumor Regions and Metabolically
Abnormal Areas
The CE lesion covered by the PRESS box was found to reside
within the CNI > 4 region for five patients, the CNI3-4 region for
two patients, and the CNI2-3 region for three patients. There were
six patients who had CE voxels outside the CNI defined regions. For
four of these patients, more than 80% of the CE lesion was within
the CNI > 2 region, and the other two patients had 50% and 12.5%
of their CE lesions within the CNI > 2 regions. The CNI regions
were within the region of T2 hyperintensity for all patients. The me-
dian percentage of the NE lesion that was outside the CNI regions
was 39.1% (min = 4.1%, max = 97.6%).
Figure 1. A 40-year-old man diagnosed with a left frontal AA. Images from left to right display the distribution of CNI values, the FSE
image with the NE LESION region (yellow), and T1-weighted post-Gd SPGR image with the CE LESION (red), NAWM (blue), and an axial
representation of the MRSI-excited region (black box). Spectra from the black box are shown at the bottom with the corresponding CNI
values displayed in each voxel.
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Spectral and Diffusion Parameters within Anatomic
Tumor Regions
Table 1 shows the median values of the metabolite and diffusion
values in the anatomic tumor regions and NAWM. Several differences
in the median metabolite levels, CNI, and diffusion values were ob-
served. Cho levels were significantly different in the NE lesion com-
pared with NAWM (P < .001), and there were substantial increases
in Cho within the CE lesion compared with both the NE lesion
and NAWM (nCho = 1.83 in CE vs 1.2 in NE). Cr values were highly
variable. There was a trend toward lower Cr values in the NE lesion
and CE lesion relative to NAWM, but the difference was only signifi-
cant for the NE lesion and this may have been driven by the higher
number of sample points. Levels of NAA were significantly lower in
the anatomic lesion regions compared with NAWM and in the CE
lesion compared with the NE lesion (nNAA = 0.3 in CE vs 0.41 in
NE). The highest Cho, lowest NAA, and, accordingly, highest CNI
levels were observed in the CE lesion (Figure 2). Combined levels
of LL were significantly higher in the CE lesion and the NE lesion
than in NAWM and were also significantly higher in the CE lesion
than in the NE lesion (LL/nNAA = 0.21 in CE vs 0.1 in NE and
0.06 in NAWM).
Normalized ADC values were significantly higher in the anatomic
regions compared with NAWM but were not significantly different
between the NE lesion and CE lesion (nADC = 1.59 in CE vs 1.67
in NE). Levels of FA were lower in the anatomic lesion regions than
in NAWM (nFA = 0.25 in CE vs 0.42 in NE), and although the
value in the CE lesion was lower than in the NE lesion, the differ-
ence was not significant. Box plots of the diffusion values are seen in
Figure 3.
Spectral and Diffusion Parameters within Metabolically
Abnormal Areas
There were clear differences in spectral and diffusion parameters
between the metabolically abnormal areas and NAWM. Cho levels
were significantly different between the NAWM and CNI2-3; there
was an increase in Cho within the CNI3-4 (nCho = 1.37) and the
CNI > 4 region (nCho = 1.83). NAA levels were significantly lower
in all of the metabolically abnormal regions compared with NAWM
and were significantly lower in regions with increasing CNI (nNAA =
0.55, 0.47, and 0.29). The CNI2-3 regions had significantly lower
Cr levels (nCr = 0.97) than the CNI > 4 (nCr = 1.06). All abnormal
metabolic regions had higher LL than NAWM with the level in
the CNI > 4 region being the highest (LL/nNAA = 0.16 vs 0.06
in NAWM).
The ADC values were significantly higher in all of the metaboli-
cally abnormal regions compared with NAWM. The CNI2-3 had
intermediate nADC levels (1.47), whereas the nADC in CNI3-4
and CNI > 4 (1.74 and 1.88) were increasing and were significantly
higher than both NAWM and CNI2-3. The levels of FA were sig-
nificantly lower in all of the metabolically abnormal regions than in
NAWM, with values that significantly decreased within regions having
higher CNI (nFA = 0.54, 0.41, and 0.34).
Differences in Levels of Lactate
Lactate-edited spectroscopy data were acquired in 30 patients. In
20 of these patients, there were spectral voxels that had visible lactate
peaks. Only nine patients in this lactate-edited cohort displayed CE and
only six of these had visible lactate peaks. Figure 4 displays a grade 3
patient whose spectral data were acquired with lactate editing. The
voxels with high Cho and low NAA intensities also displayed prominent
lactate doublets at 1.3 ppm. Figure 5 shows the box plots for median
lactate values estimated from the 20 patient data sets with visible lac-
tate peaks. Lactate was significantly higher in the NE lesion (mean
Lac = 5.37, P < .001) and in the CE lesion (mean Lac = 3.49, P = .03)
compared with NAWM (mean Lac = 1.16). The CNI2-3 (mean Lac =
2.45, P < .001), CNI3-4 (mean Lac = 3.69, P = .005), and CNI > 4
(mean Lac = 5.65, P < .001) regions all had significantly higher lactate
values than NAWM. The lactate levels were similar between CNI2-3
and CNI3-4 regions but significantly higher in the CNI > 4 region
compared with CNI2-3 (P = .002) and CNI3-4 (P = .026) regions.
Table 1. Differences of Spectral and Diffusion Parameters between NAWM, CE Lesion, and
NE Lesion.
Parameter Region Median n CE Lesion, P NE Lesion, P
nCho NAWM 1 51 .001* <.001*
CE Lesion 1.83 16 .044*
NE Lesion 1.2 51
nCr NAWM 1 51 NS .006*
CE Lesion 0.75 16 NS
NE Lesion 0.91 51
nNAA NAWM 1 51 <.001* <.001*
CE Lesion 0.3 16 .005*
NE Lesion 0.41 51
CNI NAWM −0.02 51 <.001* <.001*
CE Lesion 4.09 16 .01*
NE Lesion 2.47 51
LL/nNAA NAWM 0.06 51 .008* <.001*
CE Lesion 0.21 16 .039*
NE Lesion 0.1 51
nADC NAWM 1 51 <.001* <.001*
CE Lesion 1.59 16 NS
NE Lesion 1.67 51
nFA NAWM 1 51 .001* <.001*
CE Lesion 0.25 16 NS
NE Lesion 0.42 51
P values were calculated with the Wilcoxon signed rank test.
NS indicates not significant.
*P < .05/(k−j+1).
Figure 2. Box plots of median CNI values for all the patients. The
borders of the box plots are 25th and 75th percentiles of the
median values. The line inside the box depicts the median, and
the black dot depicts the mean of the median values. Error bars
extending outside the boxes indicate the minimum and maximum
median values for this patient population.
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Figure 3. Box plots of median normalized ADC and FA values for all the patients. The borders of the box plots are 25th and 75th
percentiles of the median values. The line inside the box depicts the median, and the black dot depicts the mean of the median values.
Error bars extending outside the boxes indicate the minimum and maximum median values for this patient population.
Figure 4. Presence of lactate within the hypointense region in a 24-year-old man diagnosed with an OA3. The spectral data were
acquired with J-difference lactate editing method. Top: Post-Gd-DTPA T1-weighted SPGR image with the spectral grid superimposed
upon it. Bottom: Corresponding summed spectra is shown on the left with gray-shaded voxels that have CNI ≥ 2. The difference lactate
spectra are shown on the right.
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Tumor Subtype Differences
Differences in metabolic and diffusion parameters for the patients
with AAs, OD3s, and OA3s were examined. Moreover, the 10th,
25th, 50th (median), 75th, and 90th percentile values for each param-
eter in each region of interest were considered. There were no statisti-
cally significant differences between the AAs and the OA3s for any of
the imaging parameters in any given region. As is shown in Table 2,
there were differences in some of the parameters that described levels
of lipid between the OD3 compared with the AA and OA3 subtypes.
This included significantly higher median, 75th, and 90th percentile
lipid values in almost all regions of OD3 compared with AA lesions
and in some of the regions of OD3 compared with OA3 lesions.
The 25th percentile of NAA was also higher in AAs than OD3s
in the CE lesion (P = .035, AA = 0.34, OD3 = 0.19). Although the
median lactate levels were higher in the CNI2-3 region of OD3s than
AAs (P = .03, AA = 2.18, OD3 = 3.68) and in the NE lesion of OA3s
than OD3s (P = .036, median (OA) = 3.66, median (OD) = 3.50),
there were only three patients with OD3 who had lactate-edited MRSI
with visible lactate peaks, and so these differences need to be further
verified in a larger population of patients.
Discussion
Whereas there have been several studies that focus on the applications
of advanced MR techniques to the assessment of tumor grade and
type, there have been relatively few studies that have provided a de-
tailed analysis of the metabolic and physiological properties of grade 3
gliomas. Even when they are included, the number of grade 3 lesions
is often small, and they are frequently grouped with a relatively large
population of grade 4 lesions under the general designation of high-
grade glioma. This means that the results presented are typically domi-
nated by the findings for grade 4 glioma. Defining the metabolic and
physiological characteristics that best represent grade 3 lesions is an im-
portant clinical problem that has so far not been adequately addressed.
Determining where within the region of hyperintensity onT2-weighted
MR images, it would be best to take tissue samples to have the highest
probability of obtaining an accurate diagnosis is an important question
that requires information about the functional properties of the le-
sion. It is for this reason that we have focused on the evaluation of
Figure 5. Box plots of median lactate levels normalized by the stan-
dard deviation of noise estimated from the J-editing PRESS spectros-
copy for the nine patients. The borders of the box plots are 25th and
75th percentiles of the median values. The line inside the box de-
picts the median, and the black dot depicts the mean of the median
values. Error bars extending outside the boxes indicate the mini-
mum and maximummedian values for this patient population.
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spatial variations in parameters that were extracted from metabolic
and physiological MR images of patients with grade 3 glioma.
The current study indicates that the median nADC values were
similar in enhancing and nonenhancing lesions from the patients with
grade 3 lesions, with values of 1.59 and 1.67. These are considerably
higher than the median values that we and others have reported in the
literature for grade 4 lesions (typically 1.4-1.5) [44] and are in the
same range that we have observed for grade 2 lesions (1.6 for oligo-
dendrogliomas and of 2.0 for astrocytomas) [45]. The interpretation
of these differences is complex because there have been a number of re-
ports in the literature that there are inverse correlations between ADC
andmarkers of tumor proliferation for brain tumors, including of Ki-67
labeling index [46], cell density [47], tumor cellularity [48], and malig-
nancy [33]. When these studies are examined in the composition of the
populations of patients being considered, it becomes clear that the re-
sults cannot be considered representative for grade 3 glioma because
there were only 2 of 47 [46], 2 of 18 [47], 0 of 56 [48], and 6 of 59
[33] of the patients with this diagnosis. In a recent study that focused
specifically on patients with grade 2 and 3 glioma, a positive rather than
a negative correlation between ADC and total tumor cell number was
reported for both types of lesions [49]. In our study of grade 4 glioma,
the lower 10th percentile of ADC values and larger areas of nADC <
1.5 were both associated with a poor survival [44], which might indi-
cate an increase in tumor burden. The median nADC levels in the
contrast enhancing and T2 hyperintense areas of grade 3 patients were
both found to be higher than 1.5 in our study, indicating smaller
nADC < 1.5 volumes, that may contribute to the improved survival,
which is typically observed in such patients. Our study is consistent
with the diffusion properties in grade 3 glioma being more similar to
those in lower-grade lesions and with the processes determining the
observed levels of nADC and nFA being associated with demyelina-
tion, edema, and disruption of normal brain as opposed to being direct
measures of tumor cell density.
There were 21 (41%) of the 51 patients in our study with areas of
low to moderate contrast enhancement. These enhancing lesions were
relatively small in volume and resided mainly within the metabolically
abnormal regions. This is consistent with the findings of Pirzkall et al.
[19], in which the enhancing lesion had the highest median nCho and
the lowest median nNAA. This was not the case for grade 4 lesions,
where the highest Cho levels were observed in the nonenhancing por-
tion of the tumor [44]. This may be due to there being more necrosis
in the contrast enhancement for grade 4 tumors, which would reduce
overall tumor cellularity. The fact that the median nADC was sig-
nificantly higher and the median nFA was significantly lower in the
enhancement of grade 3 gliomas compared with NAWM may suggest
that there was breakdown of the normal tissue architecture in these
regions that allowed for more rapid diffusion. The high median LL/
nNAA and low median nCr levels suggest that there was a tendency
toward the enhancing regions being hypoxic, which may also be a fac-
tor in inducing the breakdown of the blood-brain barrier. Overall,
these results suggest that, when present, the regions of enhancement
are the most malignant portion of untreated grade 3 glioma and pro-
vide an appropriate target for directing biopsy or surgical sampling for
diagnostic purposes.
The other anatomic region studied was the portion of the T2
hyperintensity that was nonenhancing. For 30 (59%) of 51 patients,
this comprised the entire lesion. There were highly variable median lev-
els of Cho in these regions, with 16 being lower and 35 being higher
than the levels in NAWM. Although there were variations in median
levels of NAA, these were all lower than the corresponding values
in NAWM. Differences in the normalized metabolite levels reflect the
heterogeneity in lesion characteristics between patients and underline
the motivation for using the CNI index, which defines whether a
spectrum is abnormal by combining the values of nCho and nNAA.
The fact that the LL/nNAA was higher in both the nonenhancing and
enhancing regions than the value in NAWM is consistent with the
presence of regions with hypoxia. The relatively large increase in median
nADC and decrease in median nFA in the nonenhancing regions may
be attributed to a combination of demyelination, inflammation, edema,
and tumor infiltration.
If variations in levels of CNI are used to define regions of abnormal-
ity, it is possible to obtain further insight into the relationships between
metabolite and diffusion parameters. The three regions considered
in this study represented areas that were mildly abnormal (CNI2-3),
moderately abnormal (CNI3-4), and very abnormal (CNI > 4). In
the mildly abnormal region, the Cho was higher than normal, the
Cr was slightly reduced, the NAA was almost half of the normal value,
and the LL/nNAA was significantly increased over normal. The reduc-
tion in nNAA was inversely correlated with nADC, which was in-
creased to 1.47 and the nFA was decreased to 0.54. This suggests
that the region included some tumor infiltration but that the changes
in MR parameters were dominated by reduction in neuronal function
and disruption of tissue architecture. In the moderately abnormal re-
gion, the Cho was significantly higher than normal but the Cr was
similar to the values in the mildly abnormal region. The NAA was
further reduced, the LL/nNAA further increased, the nADC further
increased and the nFA further decreased. This is consistent with the
presence of a larger number of tumor cells, together with a continued
and more extensive disruption of normal tissue.
In the highly abnormal region, there were further significant in-
creases in the median values of nCho, nCr, LL/nNAA, and nADC
and a continued decrease in the median values of nFA and nNAA
relative to the moderately abnormal region. This suggests that the
highly abnormal region included a relatively large number of tumor
cells with a higher likelihood of there being areas with reduced oxy-
genation. Taking into consideration the variations in metabolite and
diffusion parameters, it seems that, for patients with grade 3 glioma,
the area of the tumor likely to be the most malignant is at the
location of the maximum CNI, irrespective of whether the lesion
is enhancing or not. This is consistent with a recent study in non-
enhancing grade 2 and grade 3 gliomas, which investigated correla-
tions between spectroscopic parameters and histologic measures, and
reported that both the ratio of Cho/NAA and the CNI correlated with
MIB-1 proliferative index, cell density, and the ratio of proliferation to
cell death [50].
In the 30 patients who received lactate-edited spectroscopy, the re-
gion with highly abnormal metabolism was observed to have the high-
est level of lactate. This suggests that these regions exhibit anaerobic
glycolysis and are poorly oxygenated. The regions with mild and mod-
erate metabolic abnormalities and the nonenhancing lesion also had
lactate levels higher than NAWM, indicating poor oxygenation even
in areas of relatively lower tumor invasion. This is consistent with re-
cent studies from our group, which have noted voxels with lactate and
lipid peaks in some patients with grade 3 glioma [31] and reported
the presence of significant lactate and lipid peaks with volumes of these
regions varying from 0.1 to 11.8 ml [15]. The findings from this study
suggest that the MRSI data may be valuable in predicting sensitivity to
radiation therapy by delineating such poorly oxygenated regions.
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Some of the diffusion and metabolic imaging patterns were different
for subtypes of grade 3 gliomas than had previously been reported for
subtypes of treatment-naive grade 2 gliomas. In particular, it was found
that the ADC values were similar for all 3 subtypes of grade 3 gliomas,
whereas they were significantly higher for grade 2 astrocytomas and
oligoastrocytomas compared with grade 2 oligodendrogliomas [45].
The higher lipid values in subregions of OD3 compared with the
other two subtypes of grade 3 glioma is also a novel finding and may
indicate a higher tendency to cellular breakdown and the formation of
necrosis than for other histologic subtypes.
Overall, the results of the current study suggest that MRSI and
diffusion parameters provide complementary information that may
be valuable for characterizing nonenhancing regions of the anatomic
lesion and possibly directing tissue sampling for accurate diagnosis of
tumor grade. This is especially important for distinguishing patients
with grade 3 glioma from those with lower-grade lesions. Regions
of infiltrative tumor were differentiated by their increased water con-
tent (high nADC), altered normal tissue function (high Cho, low
NAA), and structure (low nFA). Regions of macroscopic tumor could
be identified by high cellularity (high CNI) and major disruptions
in the tissue structure and function (low nFA and low NAA) and hyp-
oxia (high Lac or LL/nNAA). These signatures may be of interest not
only for directing tissue sampling but also for defining the targets
for focal therapy and assessing response to therapy. Future studies that
compare presurgery MRSI and diffusion parameters with the find-
ings from image-guided tissue samples would be valuable for vali-
dating these biomarkers as clinical tools for managing patients with
grade 3 glioma.
References
[1] American Cancer Society (2010). Cancer Facts and Figures. Available at: http://
www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/
document/acspc-026238.pdf. Accessed August 18, 2010.
[2] Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W,
MacDonald D, Stitt L, and Cairncross JG (1999). Pretreatment factors predict
overall survival for patients with low-grade glioma: a recursive partitioning analy-
sis. Int J Radiat Oncol Biol Phys 45, 923–929.
[3] Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A,
Pedretti M, Polivka M, Xuan KH, Thillet J, et al. (2006). Prognostic stratifica-
tion of patients with anaplastic gliomas according to genetic profile. Cancer 107,
1891–1897.
[4] Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO,
Bernstein M, Brem H, Sloan A, et al. (2003). Survival following surgery and
prognostic factors for recently diagnosed malignant glioma: data from the
Glioma Outcomes Project. J Neurosurg 99, 467–473.
[5] Devos A, Simonetti AW, van der Graaf M, Lukas L, Suykens JA, Vanhamme L,
Buydens LM, Heerschap A, and Van Huffel S (2005). The use of multivariate
MR imaging intensities versus metabolic data from MR spectroscopic imaging
for brain tumour classification. J Magn Reson 173, 218–228.
[6] Stadlbauer A, Moser E, Gruber S, Buslei R, Nimsky C, Fahlbusch R, and
Ganslandt O (2004). Improved delineation of brain tumors: an automated
method for segmentation based on pathologic changes of 1H-MRSI metabolites
in gliomas. Neuroimage 23, 454–461.
[7] Sibtain NA, Howe FA, and Saunders DE (2007). The clinical value of proton
magnetic resonance spectroscopy in adult brain tumours. Clin Radiol 62, 109–119.
[8] Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H,
Pilatus U, and Zanella FE (2002). Clinical application of proton magnetic reso-
nance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology
44, 371–381.
[9] Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP,
and Nelson SJ (2004). 3D MRSI for resected high-grade gliomas before RT:
tumor extent according to metabolic activity in relation to MRI. Int J Radiat
Oncol Biol Phys 59, 126–137.
[10] Nelson SJ (2003). Multivoxel magnetic resonance spectroscopy of brain tumors.
Mol Cancer Ther 2, 497–507.
[11] McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS,
McDermott MW, Dillon WP, Graves EE, Pirzkall A, and Nelson SJ (2002).
Histopathological validation of a three-dimensional magnetic resonance spec-
troscopy index as a predictor of tumor presence. J Neurosurg 97, 794–802.
[12] Toyooka M, Kimura H, Uematsu H, Kawamura Y, Takeuchi H, and Itoh H
(2008). Tissue characterization of glioma by proton magnetic resonance spec-
troscopy and perfusion-weighted magnetic resonance imaging: glioma grading
and histological correlation. Clin Imaging 32, 251–258.
[13] Howe FA, Barton SJ, Cudlip SA, Stubbs M, Saunders DE, Murphy M, Wilkins
P, Opstad KS, Doyle VL, McLean MA, et al. (2003). Metabolic profiles of
human brain tumors using quantitative in vivo 1H magnetic resonance spectros-
copy. Magn Reson Med 49, 223–232.
[14] Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day
MR, Henry RG, Chang SM, DillonWP, Nelson SJ, et al. (2001). Preoperative pro-
ton MR spectroscopic imaging of brain tumors: correlation with histopathologic
analysis of resection specimens. AJNR Am J Neuroradiol 22, 604–612.
[15] Li X, Lu Y, Pirzkall A, McKnight T, and Nelson SJ (2002). Analysis of the
spatial characteristics of metabolic abnormalities in newly diagnosed glioma pa-
tients. J Magn Reson Imaging 16, 229–237.
[16] Weber MA, Giesel FL, and Stieltjes B (2008). MRI for identification of pro-
gression in brain tumors: from morphology to function. Expert Rev Neurother 8,
1507–1525.
[17] Graves EE, Nelson SJ, Vigneron DB, Verhey L, McDermott M, Larson D,
Chang S, Prados MD, and Dillon WP (2001). Serial proton MR spectroscopic
imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR
Am J Neuroradiol 22, 613–624.
[18] Li X, Jin H, Lu Y, Oh J, Chang S, and Nelson SJ (2004). Identification of MRI
and 1H MRSI parameters that may predict survival for patients with malignant
gliomas. NMR Biomed 17, 10–20.
[19] Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, Nelson
SJ, Verhey LJ, and Larson DA (2001). MR-spectroscopy guided target delinea-
tion for high-grade gliomas. Int J Radiat Oncol Biol Phys 50, 915–928.
[20] Lin A, Bluml S, and Mamelak AN (1999). Efficacy of proton magnetic reso-
nance spectroscopy in clinical decision making for patients with suspected
malignant brain tumors. J Neurooncol 45, 69–81.
[21] Pirzkall A, Nelson SJ, McKnight TR, Takahashi MM, Li X, Graves EE, Verhey
LJ, Wara WW, Larson DA, and Sneed PK (2002). Metabolic imaging of low-
grade gliomas with three-dimensional magnetic resonance spectroscopy. Int J
Radiat Oncol Biol Phys 53, 1254–1264.
[22] Nelson SJ, Graves E, Pirzkall A, Li X, Antiniw Chan A, Vigneron DB, and
McKnight TR (2002). In vivo molecular imaging for planning radiation therapy
of gliomas: an application of 1H MRSI. J Magn Reson Imaging 16, 464–476.
[23] Chan AA, Lau A, Pirzkall A, Chang SM, Verhey LJ, Larson D, McDermott
MW, Dillon WP, and Nelson SJ (2004). Proton magnetic resonance spectros-
copy imaging in the evaluation of patients undergoing gamma knife surgery for
grade IV glioma. J Neurosurg 101, 467–475.
[24] Nelson SJ, Huhn S, Vigneron DB, Day MR, Wald LL, Prados M, Chang S,
Gutin PH, Sneed PK, Verhey L, et al. (1997). Volume MRI and MRSI tech-
niques for the quantitation of treatment response in brain tumors: presentation
of a detailed case study. J Magn Reson Imaging 7, 1146–1152.
[25] Alexander A, Murtha A, Abdulkarim B, Mehta V, Wheatley M, Murray B,
Riauka T, Hanson J, Fulton D, McEwan A, et al. (2006). Prognostic signifi-
cance of serial magnetic resonance spectroscopies over the course of radiation
therapy for patients with malignant glioma. Clin Invest Med 29, 301–311.
[26] Howe FA and Opstad KS (2003). 1H MR spectroscopy of brain tumours and
masses. NMR Biomed 16, 123–131.
[27] Wald LL, Nelson SJ, Day MR, Noworolski SE, Henry RG, Huhn SL, Chang S,
Prados MD, Sneed PK, Larson DA, et al. (1997). Serial proton magnetic reso-
nance spectroscopy imaging of glioblastoma multiforme after brachytherapy.
J Neurosurg 87, 525–534.
[28] Nelson SJ (1999). Imaging of brain tumors after therapy. Neuroimaging Clin N
Am 9, 801–819.
[29] Nelson SJ, Vigneron DB, and Dillon WP (1999). Serial evaluation of patients
with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 12,
123–138.
[30] Catalaa I, Henry R, Dillon WP, Graves EE, McKnight TR, Lu Y, Vigneron
DB, and Nelson SJ (2006). Perfusion, diffusion and spectroscopy values in
newly diagnosed cerebral gliomas. NMR Biomed 19, 463–475.
Translational Oncology Vol. 5, No. 1, 2012 Spatial Characterization of Grade 3 Gliomas Ozturk-Isik et al. 17
[31] Nelson SJ, McKnight TR, and Henry RG (2002). Characterization of untreated
gliomas by magnetic resonance spectroscopic imaging. Neuroimaging Clin N Am
12, 599–613.
[32] Oh J, Cha S, Aiken AH, Han ET, Crane JC, Stainsby JA, Wright GA, Dillon
WP, and Nelson SJ (2005). Quantitative apparent diffusion coefficients and T2
relaxation times in characterizing contrast enhancing brain tumors and regions
of peritumoral edema. J Magn Reson Imaging 21, 701–708.
[33] Bulakbasi N, Guvenc I, Onguru O, Erdogan E, Tayfun C, and Ucoz T (2004).
The added value of the apparent diffusion coefficient calculation to magnetic
resonance imaging in the differentiation and grading of malignant brain tumors.
J Comput Assist Tomogr 28, 735–746.
[34] Provenzale JM, McGraw P, Mhatre P, Guo AC, and Delong D (2004). Peri-
tumoral brain regions in gliomas and meningiomas: investigation with isotropic
diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology
232, 451–460.
[35] Tsuchiya K, Fujikawa A, Nakajima M, and Honya K (2005). Differentiation
between solitary brain metastasis and high-grade glioma by diffusion tensor
imaging. Br J Radiol 78, 533–537.
[36] Goebell E, Fiehler J, Ding XQ, Paustenbach S, Nietz S, Heese O, Kucinski T,
Hagel C, Westphal M, and Zeumer H (2006). Disarrangement of fiber tracts
and decline of neuronal density correlate in glioma patients—a combined dif-
fusion tensor imaging and 1H-MR spectroscopy study. AJNR Am J Neuroradiol
27, 1426–1431.
[37] Bottomley PA (1987). Spatial localization in NMR spectroscopy in vivo. Ann N
Y Acad Sci 508, 333–348.
[38] Star-Lack J, Vigneron DB, Pauly J, Kurhanewicz J, and Nelson SJ (1997).
Improved solvent suppression and increased spatial excitation bandwidths for
three-dimensional PRESS CSI using phase-compensating spectral/spatial spin-
echo pulses. J Magn Reson Imaging 7, 745–757.
[39] Tran TK, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J,
Nelson S, and Hurd R (2000). Very selective suppression pulses for clinical MRSI
studies of brain and prostate cancer. Magn Reson Med 43, 23–33.
[40] Star-Lack J, Spielman D, Adalsteinsson E, Kurhanewicz J, Terris DJ, and
Vigneron DB (1998). In vivo lactate editing with simultaneous detection of
choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with
applications to the study of brain and head and neck tumors. J Magn Reson 133,
243–254.
[41] Nelson SJ (2001). Analysis of volume MRI and MR spectroscopic imaging
data for the evaluation of patients with brain tumors. Magn Reson Med 46,
228–239.
[42] McKnight TR, Noworolski SM, Vigneron DB, and Nelson SJ (2001). An
automated technique for the quantitative assessment of 3D-MRSI data from pa-
tients with glioma. J Magn Reson Imaging 13, 167–177.
[43] Basser PJ and Pierpaoli C (1998). A simplified method to measure the diffusion
tensor from seven MR images. Magn Reson Med 39, 928–934.
[44] Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn
KR, Chang SM, Berger MS, and Nelson SJ (2009). Relationship of pre-surgery
metabolic and physiological MR imaging parameters to survival for patients with
untreated GBM. J Neurooncol 91, 337–351.
[45] Bian W, Khayal IS, Lupo JM, McGue C, Vandenberg S, Lamborn KR, Chang
SM, Cha S, and Nelson SJ (2009). Multiparametric characterization of grade 2
glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion
imaging. Transl Oncol 2, 271–280.
[46] Calvar JA, Meli FJ, Romero C, Calcagno ML, Yanez P, Martinez AR, Lambre H,
Taratuto AL, and Sevlever G (2005). Characterization of brain tumors by MRS,
DWI and Ki-67 labeling index. J Neurooncol 72, 273–280.
[47] Gupta RK, Cloughesy TF, Sinha U, Garakian J, Lazareff J, Rubino G, Rubino L,
Becker DP, Vinters HV, and Alger JR (2000). Relationships between choline
magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative
histopathology in human glioma. J Neurooncol 50, 215–226.
[48] Kono K, Inoue Y, Nakayama K, Shakudo M, Morino M, Ohata K, Wakasa K,
and Yamada R (2001). The role of diffusion-weighted imaging in patients with
brain tumors. AJNR Am J Neuroradiol 22, 1081–1088.
[49] Stadlbauer A, Ganslandt O, Buslei R, Hammen T, Gruber S, Moser E, Buchfelder
M, Salomonowitz E, and Nimsky C (2006). Gliomas: histopathologic evaluation
of changes in directionality and magnitude of water diffusion at diffusion-tensor
MR imaging. Radiology 240, 803–810.
[50] McKnight T, Love T, Lamborn K, Berger M, Chang S, Dillon W, Bollen A,
and Nelson S (2006). Correlation of MR spectroscopic and growth character-
istics of grades II and III glioma. J Neurosurg 106(4), 660–666.
18 Spatial Characterization of Grade 3 Gliomas Ozturk-Isik et al. Translational Oncology Vol. 5, No. 1, 2012
